Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 202

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 202
---
 and other risk premiums.

| Moore Financial Consulting |

| Teli.Valuation | November 2025Page 14 of 24 |

Valuation

Methodology in Telomir’s valuation

Telomir’s valuation was performed under the income approach, using the Risk-Adjusted Net Present Value (rNPV)method. This method enhances standard DCF analysis by adjusting cash flow projections for the probability of success, i.e., adjusting for the probability of successfully advancing through clinical trials and regulatory approval. As a result, this method is also referred to as the expected net present value (eNPV) method. Among the various early-stage biotech valuation methods, the rNPV method is the most appropriate. This method is suited for valuing:

| ● | Preclinical                       
 and clinical stage biotech assets |

| ● | Novel                                           
 pharma and biotech drugs undergoing development |

| ● | Other                                                
 life sciences assets that undergo phased development |

The mechanics of rNPV involve:

| ● | Estimating                                
 clinical trial and approval probabilities |

| ● | Adjusting                                                
 cash flow projections for risk using these probabilities |

| ● | Discounting                               
 risk-adjusted cash flows to present value |

| ● | Summing                                 
 risk-adjusted cash flows to derive rNPV |

This captures the risks inherent in biotech drug development. rNPV provides a more accurate asset valuation than basic DCF as it enables conducting pharma and biotech valuation based on the stage (preclinical, Phase 1-3) of development of assets.

As mentioned in the company description, Telomir is currently in the process of developing its compound for two indications: Age Related Macular Degeneration (AMD) and Breast Cancer

We have valued Telomir under the assumption that these are the only two projects, therefore we accounted for expected income and expenses related to these indications alone and did not take into consideration developments that the Company might be performing in the future.

Another assumption made for the sake of the current valuation is that the Company will develop the two indications on its own until the successful termination of the Phase II clinical trials and following that will seek for a business agreement with a large pharma company that will perform the Phase III clinical trials (on its own account) and after the successful conclusion of the trials will continue and market the finished products. The Company will be entitled to an upfront payment at the end of Phase II and royalties from the third-party revenues.

As mentioned before, Telomir holds the marketing rights for North America only